Baker BROS. Advisors LP Increases Holdings in IDEAYA Biosciences, Inc. $IDYA

Baker BROS. Advisors LP lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 10.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,618,826 shares of the company’s stock after buying an additional 343,382 shares during the period. IDEAYA Biosciences comprises 0.7% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 20th largest position. Baker BROS. Advisors LP’s holdings in IDEAYA Biosciences were worth $125,103,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of IDEAYA Biosciences by 5.2% during the 4th quarter. Russell Investments Group Ltd. now owns 9,683 shares of the company’s stock valued at $335,000 after buying an additional 476 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of IDEAYA Biosciences by 16.1% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after buying an additional 537 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Up 2.3%

NASDAQ IDYA opened at $31.26 on Thursday. IDEAYA Biosciences, Inc. has a twelve month low of $20.50 and a twelve month high of $39.28. The firm has a market capitalization of $2.75 billion, a PE ratio of -19.54 and a beta of -0.05. The stock’s 50 day moving average is $29.78 and its 200 day moving average is $32.36.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The company had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. During the same quarter in the previous year, the company earned ($0.82) EPS. The firm’s quarterly revenue was down 39.4% compared to the same quarter last year. On average, research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IDYA. Guggenheim lifted their price target on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Wall Street Zen raised IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Mizuho decreased their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Wells Fargo & Company lifted their price target on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.69.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.